Clavispora lusitaniae
| Clavispora lusitaniae | |
|---|---|
Scientific classification 
| |
| Domain: | Eukaryota |
| Kingdom: | Fungi |
| Division: | Ascomycota |
| Class: | Saccharomycetes |
| Order: | Saccharomycetales |
| Family: | Metschnikowiaceae |
| Genus: | Clavispora |
| Species: | C. lusitaniae
|
| Binomial name | |
| Clavispora lusitaniae Rodr. Mir.
| |
| Synonyms | |
|
Candida lusitaniae Uden & Carmo Souza | |
_images_of_C_lusitaniae_on_filament-inducing_media_journal_pone_0044192.png)
Clavispora lusitaniae, formerly also known by the
Clavispora lusitaniae was first identified as a human pathogen in 1979.[2]
Clavispora lusitaniae was initially described as a rare cause of fungemia, with fewer than 30 cases reported between 1979 and 1990. However, there has been a marked increase in the number of recognized cases of candidemia due to this organism in the last two decades.[timeframe?] Bone marrow transplantation and high-dose cytoreductive chemotherapy have both been identified as risk factors for infections with this organism.[3] These patients are often neutropenic for extended periods of time, leaving them susceptible to bacterial and fungal infections, including Candidal infections. A study found that C. lusitaniae was responsible for 19% of all breakthrough fungemia infections in cancer patients between 1998 and 2013.[4]
Some investigators have theorized that the widespread use of Amphotericin B empiric antifungal therapy selects for infections with Candida lusitaniae.[5]
The